BioSpace News Archive

ASLAN Pharmaceuticals, announced that on March 28, 2022, it received a written notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC indicating that the Company is not in compliance with the US$1.00 minimum bid price requirement under the Nasdaq Listing Rules.

Assembly Biosciences, Inc. announced a grant of stock options to one new employee to purchase 19,000 shares of the Company’s common stock with an exercise price of $2.06 per share, the closing price of Assembly Bio’s common stock on April 1, 2022.

Accutar Biotechnology, Inc., a clinical stage biotechnology company focusing on artificial intelligence -empowered drug discovery, announces that the China National Medical Products Administration has cleared the company’s investigational new drug application for AC0682 for the treatment of patients with estrogen receptor -positive breast cancers.

Sanofi announced that the French Autorité des marchés financiers has approved the listing prospectus prepared by EUROAPI in connection with the intended listing of its shares on the regulated market of Euronext Paris.